Introduction to NIOX®

Management Team

Ian Johnson, Executive Chairman

Ian has spent his business career in life science and was founder and CEO of Biotrace International PLC, which was a listed company until its sale to 3M in December 2006. Inadditiontohisappointmentwith NIOX Group plc Ian is Senior Independent Director of Induction Healthcare plc. Previous appointments include Executive Chairman of Bioquell PLC, Non-executive Chairman of Redcentric PLC, Quantum Pharma PLC, Cyprotex PLC and Celsis Group Ltd, Senior Independent Director of Clinigen plc and Non-executive Director of Ergomed PLC.

Michael Roller, CFO

Experienced public company and healthcare/ life science finance director. Previously at Bioquell plc and Corin Group plc.

Jonathan Emms, COO

Jonathan has worked in the healthcare and life sciences industry for 30 years. He started his career at GSK, initially in the respiratory business and then progressing to run the UK HIV business unit. Latterly he worked for Pfizer for 20 years in a variety of roles in the various medicines and device businesses in the Pfizer portfolio. His last role was Chief Commercial Officer of Pfizer's Internal Medicines business before that UK General Manager and prior to that European Marketing Head. During his time at Pfizer, Jonathan was involved in several successful business turnaround situations, 16 product launches and a number of successful transactions.

Our Mission

To improve asthma diagnosis & management by greater patient access to FeNO testing

Asthma

  • • One of the biggest healthcare problems with 340 million asthma sufferers worldwide

  • • More than 200 million patients are at risk of an asthma attack every year

  • • Asthma is not diagnosed or is mis-diagnosed in up to 50% of patients

  • • Over 60% of patients have uncontrolled symptoms

  • • Improving asthma control saves significant medical costs per patient annually

FeNO, helping solve the asthma diagnosis puzzle

Why FeNO testing?

Features

  • • Is a precise biomarker for asthma

  • • A point of care test which is quick, easy to use and non-invasive

Benefits

  • • 7 times greater chance of a correct diagnosis

  • • Provides better treatment decisions

  • • Confirms of effectiveness of treatment and adherence to treatment

  • • Can prevent emergency hospitalisation by 50%

Strong scientific and health economic support for FeNo testing

Sustainable Market Drivers for increased FeNO testing

  • • Recognition of health economic benefits

  • • Increasing awareness of the clinical utility

  • • Rising access to asthma-related healthcare and inhaled medication

  • • Increasing access to FeNO testing devices at the point of care

  • • Rising use of new biologic treatments for asthma

Why NIOX®?

  • • The market leader authorised in most major markets and available in over 50 countries

  • • Most accurate and reproducible with strong IP

  • • First choice for healthcare professionals with over 50 million tests to date

  • • Portable and easy to use with real-time results

25 Years of NIOX Innovation

Product name

NIOX® Flex

NIOX®

NIOX MINO® NIOX VERO® NIOX PRO® NIOX MyNO®

Year launched

1998

2000

2005

2013

est. 2025

> 2025

Technology

Chemiluminescence

Electrochemical

Device price

Devices sold

£50,000 366

£25,000

£1,000 27,021 8m

£900 32,821 >43m

<£900

TBD

82

Tests sold

10

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

NIOX Group plc published this content on 25 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 March 2024 09:14:08 UTC.